ERC1671联合贝伐单抗与贝伐单抗联合安慰剂治疗复发性胶质母细胞瘤的II期研究:中期结果和与CD4+ t淋巴细胞计数的相关性

Q1 Medicine
CNS Oncology Pub Date : 2018-07-01 Epub Date: 2018-08-29 DOI:10.2217/cns-2018-0009
Daniela A Bota, Jinah Chung, Manisha Dandekar, Jose A Carrillo, Xiao-Tang Kong, Beverly D Fu, Frank Pk Hsu, Axel H Schönthal, Florence M Hofman, Thomas C Chen, Raphael Zidovetzki, Chrystel Pretto, Ankie Strik, Virgil Ejc Schijns, Apostolos Stathopoulos
{"title":"ERC1671联合贝伐单抗与贝伐单抗联合安慰剂治疗复发性胶质母细胞瘤的II期研究:中期结果和与CD4+ t淋巴细胞计数的相关性","authors":"Daniela A Bota,&nbsp;Jinah Chung,&nbsp;Manisha Dandekar,&nbsp;Jose A Carrillo,&nbsp;Xiao-Tang Kong,&nbsp;Beverly D Fu,&nbsp;Frank Pk Hsu,&nbsp;Axel H Schönthal,&nbsp;Florence M Hofman,&nbsp;Thomas C Chen,&nbsp;Raphael Zidovetzki,&nbsp;Chrystel Pretto,&nbsp;Ankie Strik,&nbsp;Virgil Ejc Schijns,&nbsp;Apostolos Stathopoulos","doi":"10.2217/cns-2018-0009","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine - composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors.</p><p><strong>Methods: </strong>In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurrent GBM were randomized to receive either ERC1671 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine<sup>®</sup> or sargramostim) and cyclophosphamide plus bevacizumab, or placebo plus bevacizumab. Interim results: Median overall survival (OS) of patients treated with ERC1671 plus bevacizumab was 12 months. In the placebo plus bevacizumab group, median OS was 7.5 months. The maximal CD4<sup>+</sup> T-lymphocyte count correlated with OS in the ERC1671 but not in the placebo group.</p><p><strong>Conclusion: </strong>The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0009","citationCount":"42","resultStr":"{\"title\":\"Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte counts.\",\"authors\":\"Daniela A Bota,&nbsp;Jinah Chung,&nbsp;Manisha Dandekar,&nbsp;Jose A Carrillo,&nbsp;Xiao-Tang Kong,&nbsp;Beverly D Fu,&nbsp;Frank Pk Hsu,&nbsp;Axel H Schönthal,&nbsp;Florence M Hofman,&nbsp;Thomas C Chen,&nbsp;Raphael Zidovetzki,&nbsp;Chrystel Pretto,&nbsp;Ankie Strik,&nbsp;Virgil Ejc Schijns,&nbsp;Apostolos Stathopoulos\",\"doi\":\"10.2217/cns-2018-0009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine - composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors.</p><p><strong>Methods: </strong>In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurrent GBM were randomized to receive either ERC1671 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine<sup>®</sup> or sargramostim) and cyclophosphamide plus bevacizumab, or placebo plus bevacizumab. Interim results: Median overall survival (OS) of patients treated with ERC1671 plus bevacizumab was 12 months. In the placebo plus bevacizumab group, median OS was 7.5 months. The maximal CD4<sup>+</sup> T-lymphocyte count correlated with OS in the ERC1671 but not in the placebo group.</p><p><strong>Conclusion: </strong>The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.</p>\",\"PeriodicalId\":10469,\"journal\":{\"name\":\"CNS Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/cns-2018-0009\",\"citationCount\":\"42\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/cns-2018-0009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/8/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2018-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/8/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 42

摘要

目的:ERC1671是一种同种异体/自体治疗性胶质母细胞瘤(GBM)疫苗,由全灭活肿瘤细胞与来自患者和三位GBM供体的肿瘤细胞裂解液混合而成。方法:在这项双盲、随机、II期研究中,贝伐单抗治疗的复发性GBM患者随机接受ERC1671联合粒细胞-巨噬细胞集落刺激因子(GM-CSF) (Leukine®或sargramostim)和环磷酰胺加贝伐单抗治疗,或安慰剂加贝伐单抗治疗。中期结果:ERC1671联合贝伐单抗治疗的患者中位总生存期(OS)为12个月。在安慰剂加贝伐单抗组中,中位生存期为7.5个月。ERC1671组的最大CD4+ t淋巴细胞计数与OS相关,而安慰剂组没有。结论:在贝伐单抗中加入ERC1671/GM-CSF/环磷酰胺可获得具有临床意义的生存获益,且毒性最小。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte counts.

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte counts.

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup> T-lymphocyte counts.

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.

Aim: ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine - composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors.

Methods: In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurrent GBM were randomized to receive either ERC1671 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine® or sargramostim) and cyclophosphamide plus bevacizumab, or placebo plus bevacizumab. Interim results: Median overall survival (OS) of patients treated with ERC1671 plus bevacizumab was 12 months. In the placebo plus bevacizumab group, median OS was 7.5 months. The maximal CD4+ T-lymphocyte count correlated with OS in the ERC1671 but not in the placebo group.

Conclusion: The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CNS Oncology
CNS Oncology Medicine-Neurology (clinical)
CiteScore
3.80
自引率
0.00%
发文量
12
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信